studing the therapeutic effect of baricitinib and its side effects and comparing it with clobetasol in LPP (Lichen Plano Pilaris)

Tehran University of Medical Sciences0 个研究点目标入组 22 人开始时间: 待定最近更新: 2022年11月21日

适应症

试验速览

暂无简介。

•Age between 15 and 70 years
•Acceptance of all provisions of informed consent regarding the plan
•Absence of contraindications for baricitinib use, including chronic renal failure with GFR below 30, severe liver failure, sensitivity to baricitinib, severe anemia with hemoglobin below 8, lymphopenia with an absolute lymphocyte count below 500, or neutropenia with an absolute neutrophil count below 1000, pregnancy and breastfeeding
•Not being pregnant and not taking OCP
•Severe and expanding multifocal disease that is a candidate for receiving systemic medication according to the opinion of the main executive of the plan.
•Not taking drugs that interact with baricitinib
•The patient's consent to enter the plan

•For any reason, the patient does not agree to enter the plan
•For any reason, the patient does not agree with the provisions of informed consent in the plan
•Contraindications to baricitinib use include chronic renal failure with GFR below 30, severe liver failure, sensitivity to baricitinib, severe anemia with hemoglobin below 8, lymphopenia with an absolute lymphocyte count below 500, or neutropenia with an absolute neutrophil count below 1000, pregnancy and breastfeeding
•Pregnancy or OCP consumption
•Local and limited disease that is not a candidate for receiving systemic and immunosuppressive drugs according to the opinion of the main executive of the plan.
•Taking drugs that interfere with baricitinib

发起方